Company
Medtech
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
120
510(k), De Novo and PMA
Device trials
93
As lead sponsor, any status
Adverse event reports
122
Received Nov 1, 2025 to Nov 19, 2026
Recall records
9
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$20.9M
1 Form D offering, 2026 to 2026
Equity
$0
Stock sold for cash
Debt and convertible notes
$20.9M
$20.9M of it convertible
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: convertible note, $20.9M raised of $20.9M sought, first sale May 22, 2026, 4 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| May 22, 2026 | Convertible note | $20.9M | $20.9M | 4 | Rule 506(b) | Form D ↗Jun 8, 2026 |
Company details
From the company's latest Form D.
- Legal name
- NV MEDTECH, Inc.
- Headquarters
- Reno, Nevada
- Incorporated
- Delaware in 2021
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Health Care
- SEC filer
- CIK 2139273 ↗
Executives, directors and promoters
As listed on the latest Form D.
4 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Medtech.
Latest FDA decisions
The 8 newest of 120 since 2015.
K260427 · Decided Oct 29, 2026 · 261 days after receipt
Device type: Ultraviolet Radiation Disinfection Chamber Device (SCS) · Hospital Medicine & Nursing
K260686 · Decided Oct 22, 2026 · 233 days after receipt
Device type: Catheter, Percutaneous, Cutting/Scoring (PNO) · Cardiology
K262674 · Decided Oct 15, 2026 · 77 days after receipt
Device type: Introducer, Catheter (DYB) · Cardiology
117 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT07912541 · 110 participants (planned) · Start Nov 2026 · Primary completion Nov 2028
Device: ADVA ACE Everolimus Eluting Coronary Stent System · For: Coronary Artery Disease; De Novo Stenosis Lesion; Coronary Stent Implantation
- Coherent Sine Burst (CSE) Electroporation System Pilot Study in Patients With Atrial FibrillationCompleted
NCT05572047 · 101 participants · Start Oct 11, 2022 · Primary completion Apr 24, 2026
Device: Arga Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System · For: Atrial Fibrillation
Sites: Split, Croatia; Zagreb, Croatia; Tbilisi, Georgia
- CardioFlow Transcatheter Mitral Valve Replacement System Pre-market Clinical InvestigationNot yet recruiting
NCT07857343 · 152 participants (planned) · Start Dec 1, 2026 · Primary completion Jan 1, 2030
Device: Microport CardioFlow Mitral Valve Replacement System · For: Degenerative Mitral Regurgitation
Sites: Beijing, China; Kunming, China; Zhengzhou, China
90 more trials with a free account
Reports received
122
Received Nov 1, 2025 to Nov 19, 2026. Includes 1 of another or unstated type.
Malfunction reports
66
54% of reports
Injury reports
55
45% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 6 | 13 | 0 | 0 |
| Jan 24 | 5 | 7 | 0 | 0 |
| Feb 24 | 1 | 5 | 0 | 0 |
| Mar 24 | 3 | 4 | 0 | 0 |
| Apr 24 | 7 | 4 | 0 | 0 |
| May 24 | 4 | 5 | 0 | 0 |
| Jun 24 | 5 | 5 | 0 | 0 |
| Jul 24 | 7 | 11 | 0 | 0 |
| Aug 24 | 4 | 12 | 0 | 0 |
| Sep 24 | 6 | 6 | 0 | 0 |
| Oct 24 | 5 | 6 | 0 | 0 |
| Nov 24 | 2 | 14 | 0 | 0 |
| Dec 24 | 9 | 6 | 0 | 1 |
| Jan 25 | 4 | 8 | 0 | 0 |
| Feb 25 | 2 | 4 | 0 | 0 |
| Mar 25 | 2 | 3 | 0 | 0 |
| Apr 25 | 2 | 7 | 0 | 0 |
| May 25 | 4 | 6 | 0 | 0 |
| Jun 25 | 7 | 14 | 0 | 0 |
| Jul 25 | 3 | 11 | 0 | 0 |
| Aug 25 | 5 | 5 | 0 | 0 |
| Sep 25 | 2 | 8 | 0 | 0 |
| Oct 25 | 4 | 7 | 0 | 0 |
| Nov 25 | 1 | 3 | 0 | 0 |
| Dec 25 | 7 | 5 | 0 | 0 |
| Jan 26 | 1 | 3 | 0 | 0 |
| Feb 26 | 2 | 5 | 0 | 0 |
| Mar 26 | 7 | 5 | 0 | 0 |
| Apr 26 | 6 | 4 | 0 | 0 |
| May 26 | 4 | 1 | 0 | 0 |
| Jun 26 | 9 | 5 | 0 | 0 |
| Jul 26 | 3 | 4 | 0 | 1 |
| Aug 26 | 5 | 7 | 0 | 0 |
| Sep 26 | 7 | 3 | 0 | 0 |
| Oct 26 | 14 | 10 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
7 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Hintermann Series Talar Implant, Left, Size 2 REF 302112Open, Classified
Z-2399-2026 · Started Mar 24, 2026 · Posted by FDA Jun 10, 2026
Reason given: Through customer complaints, the ankle replacement system was found to contain incorrect devices: Left implant packaging and labeling bears a right implant device.
Cause as FDA categorized it: Labeling Change Control · Device type: Prosthesis, Ankle, Uncemented, Non-Constrained (NTG)
Z-0118-2022 · Started Sep 22, 2021
Reason given: The firm has become aware of a software anomaly affecting ROSA One 3.1 Brain application which led to the inaccurate placement of an electrode during surgery. The firm has received 3 global complaints related to the issue. An incorrect trajectory could result in serious injury or death if undetected during surgery.
Cause as FDA categorized it: Software design · Device type: Neurological Stereotaxic Instrument (HAW)
- ROSA Brain 3.0 Application-BrainTerminated
Z-1150-2020 · Started Jan 6, 2020
Reason given: Some cross-sectional images from the image acquisitions of the patients head may not be reconstructed/displayed properly in two and three dimension views when using ROSA Brain software, potentially compromising the surgery planning.
Cause as FDA categorized it: Software design · Device type: Neurological Stereotaxic Instrument (HAW)
6 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.